AbuMweis SS, Jew S, Ames NP
The legal status follows the path of the prescription, not the molecule
In response to comments that the current approach for establishing the MS-DRG relative weights involves estimating cost from charges, we note that it still relies on data derived from hospital chargemasters as input and it still relies on an estimation methodology to convert those charges to cost
The route and dose depend on your goals and provider guidance
This matters because physicians will soon face patients who arrive already dosed, armed with AI summaries that may or may not match the evidence
#370 AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass proven, promising, fuzzy, noise, or nonsense